MedTrace Logo

ABEMA Alone or in COMBO With MK-6482

NCT04627064 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-07-25

Study results available
· View outcomes & findings →

Summary

This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC).

The names of the study drugs in this investigational combination are:

* Abemaciclib
* MK-6482

Conditions

Interventions

DRUG

Abemaciclib

Tablet taken orally

DRUG

MK-6482

Tablet taken orally

Sponsors & Collaborators

Principal Investigators

  • Toni K Choueiri, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2024-02-09
Completion
2024-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04627064 on ClinicalTrials.gov